Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dextenza vs Fluorometholone in Ocular Rosacea
NCT04839549Phase 4Withdrawn
- Sponsor
- Eye Associates of Central Texas
- Start
- Jun 2020
- Primary completion
- Nov 2022
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
01
Overview
A Phase 4 trial of ozurdex in ocular rosacea, sponsored by Eye Associates of Central Texas. Planned start Jun 2020; status: withdrawn.
02
Drugs
ozurdex
03
Conditions
ocular rosacea
Beyond the preview
Go deeper on NCT04839549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04839549.